Showing results (51-60 of 310) with videos related to
Sort By:
Pageof 31
Medical Hypotheses|April 13, 2011
Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesisAthanasios D Anastasilakis, Stergios A Polyzos, Chrysostomos D Anastasilakis, et al.Bone Reports|February 20, 2026
Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosisAthanasios D Anastasilakis, Polyzois Makras, Stergios A Polyzos, et al.European Journal of Orthodontics|December 8, 2021
Bone turnover markers in gingival crevicular fluid and blood serum of patients with fixed orthodontic appliancesDimitrios Kloukos, Eleni Mavrogonatou, Dimitris Kletsas, et al.Pituitary|February 1, 2011
Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans' cell histiocytosisAthanasios D Anastasilakis, Gregory A Kaltsas, Georgios Delimpasis, et al.Hormones (Athens, Greece)|April 17, 2020
Management of parathyroid disorders: recommendations of the working group of the Bone Section of the Hellenic Endocrine SocietyPolyzois Makras, Maria P Yavropoulou, Evanthia Kassi, et al.Therapeutics and Clinical Risk Management|July 7, 2012
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumabAthanasios D Anastasilakis, Konstantinos A Toulis, Stergios A Polyzos, et al.The Journal of Clinical Endocrinology and Metabolism|June 22, 2013
Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trialAthanasios D Anastasilakis, Stergios A Polyzos, Athina Gkiomisi, et al.Maturitas|April 9, 2021
Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerationsStergios A Polyzos, Athanasios D Anastasilakis, Zoe A Efstathiadou, et al.Journal of Clinical Medicine|September 28, 2023
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of DenosumabAthanasios D Anastasilakis, Polyzois Makras, Julien Paccou, et al.Journal of Clinical Medicine|January 7, 2021
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative ReviewAthanasios D Anastasilakis, Polyzois Makras, Maria P Yavropoulou, et al.Pageof 31